MX2023008626A - Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas. - Google Patents

Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.

Info

Publication number
MX2023008626A
MX2023008626A MX2023008626A MX2023008626A MX2023008626A MX 2023008626 A MX2023008626 A MX 2023008626A MX 2023008626 A MX2023008626 A MX 2023008626A MX 2023008626 A MX2023008626 A MX 2023008626A MX 2023008626 A MX2023008626 A MX 2023008626A
Authority
MX
Mexico
Prior art keywords
klotho
protein
subject
dosage
same
Prior art date
Application number
MX2023008626A
Other languages
English (en)
Inventor
Joseph F Tarsio
Dinesh Raturi
James R Plante
Original Assignee
Klotho Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klotho Therapeutics Inc filed Critical Klotho Therapeutics Inc
Publication of MX2023008626A publication Critical patent/MX2023008626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se dan a conocer proteínas y variantes Klotho recombinantes, ácidos nucleicos que codifican las mismas, líneas celulares y cultivos en suspensión que expresan las mismas, y un método de producción y administración de las mismas. Las proteínas incluyen atributos que prolongan la solubilidad o vida media, como la glucosilación y etiquetas de proteínas de fusión. Las proteínas tienen por lo menos 85% de identidad de secuencias de aminoácidos con una porción de Klotho alfa humana isoforma 1. Los protocolos de tratamiento incluyen determinar el nivel de Klotho soluble sérica en un sujeto, calcular una dosificación de la proteína suficiente para elevar el nivel de Klotho soluble sérica en el sujeto a un nivel predeterminado, administrar la dosificación de proteína al sujeto, tal como por inyección de bolo o inyección gradual, determinar una tasa de decaimiento de proteína Klotho en el suero del sujeto después de la administración de la primera dosificación, calcular un tiempo y cantidad de una dosificación subsecuente de la proteína Klotho, y administrar la dosificación subsecuente de proteína Klotho al sujeto.
MX2023008626A 2016-06-02 2018-11-29 Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas. MX2023008626A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662344743P 2016-06-02 2016-06-02
US201662375046P 2016-08-15 2016-08-15
US201662401600P 2016-09-29 2016-09-29
US201662425237P 2016-11-22 2016-11-22
US201762456318P 2017-02-08 2017-02-08

Publications (1)

Publication Number Publication Date
MX2023008626A true MX2023008626A (es) 2023-08-08

Family

ID=60477890

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014753A MX2018014753A (es) 2016-06-02 2017-06-02 Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.
MX2023008626A MX2023008626A (es) 2016-06-02 2018-11-29 Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018014753A MX2018014753A (es) 2016-06-02 2017-06-02 Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.

Country Status (9)

Country Link
EP (1) EP3464608A4 (es)
JP (2) JP2019526272A (es)
KR (2) KR20230125857A (es)
CN (2) CN109219663A (es)
AU (1) AU2017272349B2 (es)
BR (1) BR112018073909A2 (es)
CA (1) CA3025461A1 (es)
MX (2) MX2018014753A (es)
WO (1) WO2017210607A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996555A (zh) * 2016-11-22 2019-07-09 克洛索治疗有限公司 新颖重组klotho蛋白及其组合物和方法
CN108333355B (zh) * 2018-02-01 2020-05-26 黄曙 Klotho蛋白在制备诊断胃肠道间质瘤危险度的试剂中的用途
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用
WO2020160617A1 (en) * 2019-02-05 2020-08-13 Helium 3 Biotech Pty Ltd A membrane protein expression and distribution modulating composition and method of use thereof
RU2712770C1 (ru) * 2019-05-21 2020-01-31 Всеволод Викторович Мелехин Способ ингибирования роста опухолевых клеток
IT201900007446A1 (it) 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
CN112195165A (zh) * 2020-10-15 2021-01-08 广东药科大学 一种抗衰老分泌型Klotho蛋白及其编码基因、重组表达载体与应用
CN114487218B (zh) * 2020-10-23 2023-11-14 北京红惠新医药科技有限公司 β-烟酰胺单核苷酸的分析方法
CN112915193B (zh) * 2021-03-05 2022-09-13 南方医科大学南方医院 Kp-1在制备治疗慢性肺病的药物中的用途
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113215199A (zh) * 2021-04-29 2021-08-06 广州博识生物科技有限公司 一种Klotho+/-基因缺失斑马鱼
WO2022243519A1 (en) * 2021-05-21 2022-11-24 Universitat Autònoma De Barcelona Secreted splicing variant of klotho for treating bone disorders
CN113409306A (zh) * 2021-07-15 2021-09-17 推想医疗科技股份有限公司 一种检测装置、训练方法、训练装置、设备和介质
WO2023172444A2 (en) * 2022-03-08 2023-09-14 Mayo Foundation For Medical Education And Research Senotherapeutic agents and alpha-klotho polypeptides
WO2023218445A1 (en) * 2022-05-08 2023-11-16 Ichilov Tech Ltd. Klotho derivatives with modified structure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027885A1 (fr) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN102861343A (zh) * 2012-10-17 2013-01-09 南方医科大学 分泌型Klotho在制备治疗慢性肾脏病的药物中的应用
CN116656605A (zh) * 2014-04-16 2023-08-29 朱诺治疗有限公司 用于扩增细胞群的方法、试剂盒及装置

Also Published As

Publication number Publication date
WO2017210607A1 (en) 2017-12-07
EP3464608A4 (en) 2020-01-29
JP2019526272A (ja) 2019-09-19
MX2018014753A (es) 2019-06-17
AU2017272349A1 (en) 2018-11-22
EP3464608A1 (en) 2019-04-10
KR20230125857A (ko) 2023-08-29
BR112018073909A2 (pt) 2019-02-26
KR20190015711A (ko) 2019-02-14
KR102570250B1 (ko) 2023-08-29
JP2023123565A (ja) 2023-09-05
CA3025461A1 (en) 2017-12-07
CN116478907A (zh) 2023-07-25
CN109219663A (zh) 2019-01-15
AU2017272349B2 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2023008626A (es) Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas.
MX2019005687A (es) Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas.
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
WO2012065072A3 (en) IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
ZA202002094B (en) Trispecific proteins and methods of use
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
MX2017014083A (es) Polipeptido de fusion anti-cancer.
HRP20191966T1 (hr) Stabilizirani neproteinski klostridijalni pripravci toksina
MX2018016295A (es) Interferon porcino pegilado y metodos de utilizacion del mismo.
HRP20171931T1 (hr) Farmaceutska formulacija koja obuhvaća biofarmaceutski lijek
NZ711567A (en) Antibody formulations
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
CU24314B1 (es) Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos
DE23189888T1 (de) Flüssige pharmazeutische zusammensetzung von adalimumab
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
RU2016105462A (ru) Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
MX2018014631A (es) Formulacion de neurotoxina.
MX2021003726A (es) Particulas de arn que comprenden polisarcosina.
MY193519A (en) Method for decreasing immunogenicity of protein and peptide
IN2014DN06920A (es)
WO2021222639A3 (en) Recombinant human metapneumovirus f proteins and their use